Upadacitinib in Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs: Efficacy and Safety Through 5 Years (SELECT-NEXT)

Rheumatoid Arthritis

Factors associated with biological and targeted synthetic disease-modifying antirheumatic drug initiation for rheumatoid arthritis in underserved patient groups in England and Wales, UK: a national cohort study

Lancet Rheumatol

Russell MD, Gibson M, Zuckerman B, Kumar K, Dubey S, Adas MA, Alveyn E, Patel S, Yang Z, Bechman K, Price E, Gallagher S, Cope AP, Norton S, Galloway JB

doi: 10.1016/S2665-9913(24)00221-2

Rheumatoid Arthritis

Disease-modifying antirheumatic drugs and risk of incident interstitial lung disease among patients with rheumatoid arthritis: A systematic review and meta-analysis

Semin Arthritis Rheum

Zhang Q, McDermott GC, Juge PA, Chang SH, Vanni KM, Qian G, Bade KJ, Mueller KT, Kowalski EN, Saavedra AA, Sparks JA

doi: 10.1016/j.semarthrit.2024.152561

Rheumatoid Arthritis

Preferences for tapering biologic disease-modifying antirheumatic drugs among people with rheumatoid arthritis - a discrete choice experiment

Arthritis Care Res (Hoboken)

Chan SJ, Stamp LK, Treharne GJ, Cheung JMY, Dalbeth N, Grainger R, Stebbings S, Marra CA

doi: 10.1002/acr.25437

Further Publications Rheumatology

Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis refractory to biologic therapy: 2-year clinical and radiographic results from the open-label extension of the SELECT-AXIS 2 study

Arthritis Res Ther

Baraliakos X, van der Heijde D, Sieper J, Inman RD, Kameda H, Maksymowych WP, Lagunes-Galindo I, Bu X, Wung P, Kato K, Shmagel A, Deodhar A

doi: 10.1186/s13075-024-03412-8

Rheumatoid Arthritis

Effectiveness of janus kinase inhibitors compared with biologic disease modifying anti-rheumatic drugs on pain reduction in rheumatoid arthritis: Results from a nationwide Swedish cohort study

Arthritis Rheumatol

Eberhard A, Di Giuseppe D, Askling J, Bergman S, Bower H, Chatzidionysiou K, Forsblad-d'Elia H, Kastbom A, Olofsson T, Frisell T, Turesson C

doi: 10.1002/art.43014

Psoriatic Arthritis

Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies

Rheumatol Ther

Mease PJ, Merola JF, Tanaka Y, Gossec L, McInnes IB, Ritchlin CT, Landewé RBM, Asahina A, Ink B, Heinrichs A, Bajracharya R, Shende V, Coarse J, Coates LC

doi: 10.1007/s40744-024-00708-8

Further Publications Rheumatology

Long-term safety and efficacy of anti-GM-CSF otilimab in patients with rheumatoid arthritis: long-term extension of three phase 3 randomised trials (contRAst X)

BMJ Open

Weinblatt ME, Taylor PC, McInnes IB, Atsumi T, Strand V, Takeuchi T, Bracher M, Brooks D, Curtis P, Gupta A, Nijhawan R, O'Shea C, Rayner K, Saurigny D, Shelton C, Wang M, Wang R, Fleischmann RM

doi: 10.1136/bmjopen-2024-088869

Rheumatoid Arthritis

Predictors of arthritis development in individuals at risk of rheumatoid arthritis: a 5-year follow-up study from a large cohort

Ann Rheum Dis

Frazzei G, Landewé RBM, Wagenaar C, van de Stadt LA, van Schaardenburg D, Tas SW, van Vollenhoven RF

doi: 10.1016/j.ard.2025.01.042

Psoriatic Arthritis

Four-year effectiveness, safety and drug retention rate of secukinumab in psoriatic arthritis: a real-life Italian multicenter cohort

Arthritis Res Ther

Ramonda R, Lorenzin M, Chimenti MS, Atzeni F, Semeraro A, D'Angelo S, Selmi C, Ortolan A, Marchesoni A, Manara M, Luchetti Gentiloni MM, Santo L, Salvarani C, Cauli A, Rossini M, Amato G, Cozzi G, Scagnellato L, Ferraioli M, Carriero A, Fracassi E, Giorgio F, Doria A, Foti R, Carletto A, on behalf Spondyloarthritis and Psoriatic Arthritis SIR Study Group “Antonio Spadaro”

doi: 10.1186/s13075-024-03401-x

Related content

Factors associated with biological and targeted synthetic disease-modifying antirheumatic drug initiation for rheumatoid arthritis in underserved patient groups in England and Wales, UK: a national cohort study

Disease-modifying antirheumatic drugs and risk of incident interstitial lung disease among patients with rheumatoid arthritis: A systematic review and meta-analysis

Preferences for tapering biologic disease-modifying antirheumatic drugs among people with rheumatoid arthritis - a discrete choice experiment

Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis refractory to biologic therapy: 2-year clinical and radiographic results from the open-label extension of the SELECT-AXIS 2 study

Effectiveness of janus kinase inhibitors compared with biologic disease modifying anti-rheumatic drugs on pain reduction in rheumatoid arthritis: Results from a nationwide Swedish cohort study

Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies

Long-term safety and efficacy of anti-GM-CSF otilimab in patients with rheumatoid arthritis: long-term extension of three phase 3 randomised trials (contRAst X)

Predictors of arthritis development in individuals at risk of rheumatoid arthritis: a 5-year follow-up study from a large cohort

Four-year effectiveness, safety and drug retention rate of secukinumab in psoriatic arthritis: a real-life Italian multicenter cohort